Adding SERDs to the adjuvant armamentarium: Selective estrogen receptor degraders are vying to join aromatase inhibitors and selective estrogen receptor modulators as therapy after the initial treatment of breast cancer

In the United States, breast cancer is second only to skin cancer as the malignancy most commonly diagnosed among women. Nearly 300,000 women will be diagnosed with invasive breast cancer [...]